Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Phillips, K. A. Articles by Rasmussen, S. A. Search for Related Content PubMed Citation Articles by Phillips, K. A. Articles by Rasmussen, S. A. Somatoform Disorders Antidepressants

Change in Psychosocial Functioning and Quality of Life of Patients With Body Dysmorphic Disorder Treated With Fluoxetine: A Placebo-Controlled Study

Received Aug. 29, 2003; revision received Oct. 11, 2003; accepted Dec. 4, 2003. From Butler Hospital and the Department of Psychiatry and Human Behavior, Brown Medical School. Address correspondence to Dr. Phillips, Butler Hospital, 345 Blackstone Blvd., Providence, RI 02906; Katharine_Phillips{at}brown.edu (e-mail).

In a 12-week placebo-controlled study of fluoxetine in the treatment of body dysmorphic disorder, the authors investigated change in psychosocial functioning and mental health-related quality of life in 60 subjects. The subjects were assessed with the LIFE-RIFT (a measure of impaired functioning), Social and Occupational Functioning Scale (SOFAS), and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) before and after receiving fluoxetine or placebo. At baseline, the patients had impaired psychosocial functioning and markedly poor mental health-related quality of life. Compared to placebo, fluoxetine was associated with significantly greater improvement in LIFE-RIFT and SOFAS scores and with improvement on the mental health subscale of the SF-36 that approached significance. Decrease in the severity of body dysmorphic disorder, as measured by the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, was significantly correlated with improvement in functioning and quality of life.

This article has been cited by other articles:

				J. Arehart-Treichel SSRIs May Offer Modest Benefit In Body Dysmorphic Disorder Psychiatr News, October 15, 2004; 39(20): 23 - 23. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2004 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us